Tuberculosis (TB) continues to be a major public health problem, especially in developing countries and South East Asia Region. India alone accounted for an estimated one quarter (26%) of the global TB burden in 2010[@ref1][@ref2]. The biologically active form of vitamin D- 1, 25-dihydroxy vitamin D has been shown to affect innate immunity by modulating macrophage function; this may enhance protection against tuberculosis infection[@ref3][@ref4]. Vitamin D also upregulates antimicrobial peptide cathelicidin and enhances killing of intracellular *M. tuberculosis*. In the absence of adequate vitamin D levels, triggering of toll-like receptors of macrophage by *M. tuberculosis* antigen results in impaired production of cathelicidin[@ref5][@ref6].

If one considers that the deficient immuno-modulatory function in states of vitamin D deficiency increases the risk of tuberculosis, the pertinent question arises whether there is any link between the levels of deficiency and extent or severity of tubercular disease. The next relevant issue is whether vitamin D deficiency has any detrimental effect on the response and outcome of standard anti-tubercular therapy. The answers to these queries could direct us in planning vitamin D supplementation in TB patients and also in deciding whether all levels of deficiency of vitamin D need to be corrected. There are only a few studies which have addressed these issues, none so in the paediatric population.

With this background, 25-hydroxy vitamin D levels were measured in children who had been enrolled in a randomized controlled trial (RCT) to study the effect of micronutrient supplementation in paediatric intrathoracic tuberculosis. The objective of this study was to evaluate the association of low serum 25-hydroxy vitamin D levels with the types and outcome of intrathoracic tubercular disease.

Material & Methods {#sec1-1}
==================

This study was conducted in 266 children enrolled in a placebo controlled, randomized controlled trial on micronutrient supplementation in children with intrathoracic tuberculosis. All consecutive children of either sex, between 6 months to 15 yr of age, suffering from probable pulmonary and/or pleural tuberculosis were recruited in 2009-2011 from the Paediatric TB Clinic of two tertiary care centres of New Delhi (All India Institute of Medical Sciences and Kalawati Saran Children Hospital); ethical approval was obtained from both institutions. Diagnosis of probable intrathoracic tuberculosis was based on clinico-radiological criteria[@ref7]. After obtaining written informed consent from the parents, children with probable TB were enrolled in the study.

Induced sputum and gastric lavages were collected on two consecutive days and examined for acid fast bacilli (AFB) by Ziehl-Neelsen (Z-N) staining and cultured on automated BACTEC-MGIT 960 system, (Becton, Dickinson & Company, USA). Cell count, biochemistry, Z-N stain, and culture for AFB and bacteria were performed on pleural fluid. The procedures were performed at both the sites. Pleural fluid was collected from children who had a pleural effusion.

Based on chest X-ray findings, children with probable intrathoracic tuberculosis were categorized into three categories: primary pulmonary complex (PPC), progressive pulmonary disease (PPD) and pleural effusion (PE)[@ref7]. PPC included lymph node with small alveolar shadow; PPD group included consolidation, cavitatory lesion, miliary tuberculosis and multiple mediastinal adenopathy with or without parenchymal lesion.

Outcome of antitubercular therapy was measured in two groups: cured and extension of therapy. Children were declared "cured", if there was significant resolution of radiologic findings (\>2/3^rd^) and symptoms at six months of therapy and the treatment was discontinued. Extension of therapy included children whose category I therapy was extended or changed to category II/ second line antitubercular drugs for persistent symptoms or poor resolution of radiographic findings. Induced sputum/ gastric lavage conversion at two months was also assessed in the group of children who had a microbiological confirmation of diagnosis at baseline. All children with diagnosis of tuberculosis were treated with daily antitubercular therapy and were monitored as per standardized protocol[@ref8]. Detailed history, clinical examination and anthropometric measurements were recorded for all enrolled patients.

*Measurement of 25-hydroxy vitamin D*: Levels of 25-hydroxy vitamin D were measured together for all samples after the RCT had ended. About 3 ml blood was collected prior to starting antitubercular therapy in plain zinc free tubes for micronutrient estimation. Serum was separated within one hour and one aliquot of 300 μl was stored at -20°C till further analysis. Similar sample collections were also performed at two and six months of therapy. Levels of 25-hydroxy vitamin D levels were measured from the stored serum samples by chemiluminescent immunoassay (CLIA) technology using Liaison^®^ 310600 system (DiaSorin Inc; USA) following the manufacturer\'s protocol[@ref9]. The analytical measurement range for the DiaSorin LIAISON 25-hydroxy vitamin D Total Assay is 4 to 150 ng/ml. The lowest reportable value is 4 ng/ml, based on an inter-assay precision that approximates 20 per cent CV.

*Statistical analysis*: Children were classified into three groups according to circulating 25-hydroxy vitamin D levels. Those with serum 25-hydroxy vitamin D level \<12 ng/ml were grouped as deficient, 12 to \<20 ng/ml as insufficient and ≥20 ng/ml as sufficient[@ref10]. Analysis was done using the software Stata, version 9 (STATA Corp, College Station, TX, USA). Chi-squared/Fisher\'s exact test and ANOVA were used for categorical and continuous variables as appropriate. The baseline 25-hydroxy vitamin D levels were log transformed and then we calculated the geometric mean and 95% confidence intervals. Height-for-age (HA) and weight-for-age (WA) 'Z' scores were computed using the nutritional anthropometry module of Epi Info version 5 software (Centers for Disease Control and Prevention, Atlanta, US), based on the National Center for Health Statistics (NCHS) - WHO reference curves[@ref11]. The association between the baseline 25-hydroxy vitamin D levels and the outcome was assessed. In the trial, 140 children received vitamin D supplementation while others did not. To adjust for the influence of other factors such as vitamin D supplementation, age, gender, *M. tuberculosis* positivity, weight-for-age Z-score, 25-hydroxy vitamin D levels at two and six months, the category of antitubercular therapy received (Cat I or Cat III)[@ref8] Cox\'s proportional hazard regression model was performed with 25-hydroxy vitamin D level as a time-dependent covariate; except in children who died, the outcome (cure) was assessed at 6 months of antitubercular therapy.

Results {#sec1-2}
=======

*Characteristics of the study population*: This study included 266 children (152, 57.1% females) with probable intrathoracic tuberculosis. The mean age was 106.9 ± 43.7 months. Most children were vaccinated with BCG (75.9%); 97 (36.5%) children had positive history of contact with tuberculosis patient. Chest X-ray was suggestive of primary pulmonary complex (PPC), progressive pulmonary disease (PPD) and pleural effusion in 81 (30.5%), 149 (56%) and 36 (13.5%) subjects, respectively. Microbiological confirmation for *Mycobacterium tuberculosis* by positive MGIT culture was obtained in 94 (35.3%) cases.

*Baseline serum 25-hydroxy vitamin D levels*: Median serum 25-hydroxy vitamin D level was 8 ng/ml (IQR 5, 12). One hundred and eighty six (69.9%) children were vitamin D deficient (serum 25-hydroxy vitamin D \<12 ng/ml), 55 (20.7%) were insufficient (12 to \<20 ng/ml) and only 25 (9.4%) were vitamin D sufficient (≥ 20 ng/ml). The median (IQR) baseline serum 25-hydroxy vitamin D levels in girls were lower \[7 (5, 11) ng/ml\] as compared to boys \[10 (6, 14) ng/ml\]; *P*\<0.01. The 25-hydroxy vitamin D levels were not different in the severely underweight and stunted children as compared to the well nourished ones.

*Association of baseline serum 25-hydroxy vitamin D levels with type of intrathoracic TB*: Of the 81 primary pulmonary complex cases, 75 per cent had a deficient 25-hydroxy vitamin D level as compared to 67 per cent of progressive pulmonary disease cases and 69 per cent of pleural effusion cases ([Table I](#T1){ref-type="table"}). The geometric mean (95% CI) of baseline 25-hydroxy vitamin D levels in children with PPC, PPD and PE were 7.69 (6.96, 8.67), 8.17 (7.39, 9.02) and 8.0 (6.82, 9.49) ng/ml, respectively. There was no significant difference in 25-hydroxy vitamin D levels between microbiologically confirmed TB and probable TB cases; median (IQR) 25-hydroxy vitamin D levels in both groups being 8 (5.5, 12.5) and 8.5 (5, 12) ng/ml, respectively.
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Association of baseline 25-hydroxy vitamin D level with type of intrathoracic tuberculosis
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*Association of baseline serum 25-hydroxy vitamin D levels with outcomes of intrathoracic TB*: Thirty one children needed extension/change of therapy or died; their median (IQR) baseline 25 hydroxy vitamin D serum level was 6 (5, 11) ng/ml as compared to 8 (5, 13) ng/ml in 235 children who were cured. The children who did not demonstrate sputum conversion after intensive phase of antitubercular therapy had lower median (IQR) baseline 25-hydroxy vitamin D levels \[7 (5, 9) ng/ml; n=27\] as compared to those who did \[9 (6, 14) ng/ml; n=67\]; *P*\<0.05. [Table II](#T2){ref-type="table"} shows the proportions of the patients who were cured and those who converted at two months in the three categories based on baseline 25-hydroxy vitamin D levels; children who were deficient or insufficient were less likely to convert at two months as compared to those who were 25-hydroxy vitamin D sufficient.

###### 
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The median (IQR) serum 25-hydroxy vitamin D levels at two months were comparable in children who needed extension/change of therapy \[7 (5, 14) ng/ml; n=17\] as compared to children who were cured \[9 (6, 17) ng/ml; n=175\]. However, the median (IQR) serum 25-hydroxy vitamin D levels at six months were lower in children who needed extension of therapy \[5 (4, 9) ng/ml; n=15\] as compared to children who were cured \[9 (5- 15) ng/ml; n=175\]; *P*\<0.05.

*Association of vitamin D supplementation with outcomes of intrathoracic TB*: One hundred forty (52.6%) children received vitamin D supplementation in the trial. Hypovitaminosis D (25-hydroxy vitamin D \< 20 ng/ml) at baseline was documented in 126 of 140 (90%) children who received vitamin D and in 114 of 126 (90.4%) who did not. The median (IQR) 6-month serum 25-hydroxy vitamin D levels were higher in the supplemented group \[10 (6, 21.5) ng/ml; n=97\] as compared to those who did not receive vitamin D \[6 (4, 11) ng/ml; n=93\]; *P*\<0.0001. In the vitamin D supplemented group, 87 of 99 (87.9%) of the vitamin D deficient children were cured at six months as compared to 27 of 28 (96.4%) of vitamin D insufficient children and 12 of 13 (92.3%) of vitamin D sufficient children. Similarly, in children who did not receive vitamin D supplementation, 75 of 87 (86.2%) of the vitamin D deficient children were cured at six months as compared to 23 of 27 (85.1%) of vitamin D insufficient children and 11 of 12 (91.7%) of vitamin D sufficient children. There was no association between the outcome and baseline 25-hydroxy vitamin D levels in the sub-groups by supplementation.

On Cox\'s proportional hazard regression model, baseline 25-hydroxy vitamin D status, age, gender, *M. tuberculosis* positivity, weight for age Z-score, vitamin D supplementation received, the serum 25-hydroxy vitamin D level at baseline, two months and at six months as a time dependent variable, and the category of antitubercular therapy received (Cat I or Cat III) did not influence the outcome.

Discussion {#sec1-3}
==========

Our study showed that baseline serum 25-hydroxy vitamin D levels in children with intrathoracic tuberculosis were not different in different types/ categories of disease. The children who were cured, had higher median 25-hydroxy vitamin D levels at baseline, two and six months as compared to children who needed extension/change of therapy; however, using the Cox\'s proportional hazard regression model, no association was observed. The children who remained positive for *M. tuberculosis* in respiratory samples at the end of two months of therapy had lower baseline 25-hydroxy vitamin D levels as compared to those who showed conversion.

Most of the studies conducted in adult population have suggested that 25-hydroxy vitamin D levels are lower in individuals with tuberculosis[@ref12][@ref13][@ref14][@ref15][@ref16][@ref17]. A study done by Ho-Pham *et al*[@ref12] on Vietnamese population showed that prevalence of vitamin D insufficiency was 35.4 and 45.3 per cent in men and women with TB, respectively. Other studies done on Africans, Pakistani, Ugandan, Gujarati Asians in West London and immigrant population from Sub-Saharan Africa living in Australia also suggested that 25-hydroxy vitamin D levels were low in adult TB patients[@ref14][@ref15][@ref16][@ref17]. Studies from paediatric population are scarce, but those available show lower 25-hydroxy vitamin D levels in children with tuberculosis as compared to controls[@ref18][@ref19][@ref20]. A study done by Genmaa *et al*[@ref20] showed that 25-hydroxy vitamin D levels were low (\<20 ng/ml) in Mongolian children with tuberculosis (7 ± 4 ng/ml). Likewise, another study which was done in Australia included refugee children and showed that 25-hydroxy vitamin D levels were significantly lower in children with latent tuberculosis and TB infection (64.2 and 81.8%, respectively)[@ref21].

Our study also showed that most of the children with intrathoracic tuberculosis were either vitamin D deficient (69.9%) or insufficient (20.7%). We are unable to comment whether this is because of association of low 25-hydroxy vitamin D levels with tuberculosis or simply reflects the vitamin D deficient or insufficient status of the general population. It has been reported that 75-85 per cent of Indian school-going children have vitamin D deficiency or insufficiency[@ref22].

Many studies have evaluated the association of tuberculosis with low serum vitamin level and the immunomodulatory effects of vitamin D. But there are no reports available on association of severity of vitamin D deficiency and types of tubercular disease in children. A study conducted on South Korean adults showed that baseline serum 25-hydroxy vitamin D levels were low in all patients with tuberculosis and levels did not differ between patients with pulmonary and extrapulmonary tuberculosis[@ref23]. In our study, we did not observe any difference in the serum levels of 25-hydroxy vitamin D in the three types of the tuberculosis (PPC, PPD and PE).

There has been speculation on whether vitamin D supplementation can hasten the cure of tuberculosis when used in conjunction with standard antitubercular therapy. If 25-hydroxy vitamin D levels can be shown to have any correlation with the outcome of tubercular disease, this mode of intervention may be logical. In our study, a relation was observed between sputum conversion at two months with the baseline 25-hydroxy vitamin D levels. We observed lower baseline 25-hydroxy vitamin D levels in children who did not show sputum conversion than who did. There are a few other studies which have looked into this aspect of relationship between vitamin D and tuberculosis and they have also displayed a poor outcome in the 25-hydroxy vitamin D deficient population. A Japanese study conducted by Sato *et al*[@ref24] has suggested that low serum 25-hydroxy vitamin D level may not only increase the risk of developing active TB but may also be related to the poor treatment outcomes, which was measured by time taken to obtain three consecutive negative sputum smears or TB bacteria cultures. This study included only 38 subjects with tuberculosis and because of small sample size, results of this study cannot be extrapolated to whole population. Rathored *et al*[@ref25] studied 354 multidrug resistant (MDR) and 338 drug sensitive Indian TB patients and found that 25-hydroxy vitamin D concentrations were lower in MDR group than the drug sensitive TB patients. Also in MDR-TB, smear conversion time was negatively correlated with 25-hydroxyvitamin D (Spearman\'s ρ coefficient −0.14, *P*=0.03), but culture conversion time did not show any such significant relationship[@ref25]. An older Indonesian study on 40 patients of pulmonary tuberculosis documented that the disease was less extensive in patients who had higher 25-hydroxy vitamin D levels[@ref26]. Sputum conversion rate at two months have been considered as a predictor of relapse of tuberculosis in adults with longer time to conversion being associated with higher relapse rates[@ref27][@ref28].

Since this study was a subset of a randomized control trial, almost half of children received vitamin D as a part of micronutrient supplementation. This supplementation did not affect the outcome or influence the effect of vitamin D deficiency as demonstrated by multivariate analysis. Our children were biochemically deficient/insufficient in vitamin D, but they did not manifest as clinical rickets. None of these children were given therapeutic vitamin D supplementation as all assays were done after the completion of clinical trial and the children did not have clinical signs/symptoms of rickets.

The strengths of this study included a large sample size and the use of a sensitive technique for 25-hydroxy vitamin D level estimation. But the study had some limitations. We did not estimate vitamin D intake, duration of sun exposure and degree of skin pigmentation, all of which might have helped in explaining the low serum 25-hydroxy vitamin D levels. The study was carried out in children enrolled in a randomized controlled trial and not as an independent study. We did not enrol healthy controls, which would have helped us determine the role of low 25-hydroxy vitamin D levels in predisposing to development of tuberculosis in children. The number of children with poor outcome was small; a much larger sample size will be needed to have the appropriate power to determine the differences in vitamin D status.

In conclusion, majority of the enrolled children with microbiologically confirmed and probable intrathoracic tuberculosis demonstrated low serum levels of 25-hydroxy vitamin D (deficient and insufficient levels) and the levels were not associated with type and outcome of TB. However, children who did not demonstrate sputum conversion after intensive phase of antitubercular therapy had lower baseline 25-hydroxy vitamin D levels as compared to those who did.
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